Novo Seeds co-leads Adcendo’s EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

  • Financing is the largest Series A for a Danish biotech company
  • Novo Seeds played instrumental role in supporting Adcendo from inception
  • Plans to build a pipeline of ADCs directed at novel cancer targets

Copenhagen, Denmark, 29 April 2021 – Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today an investment in Adcendo, a Danish biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers. The EUR 51 million (US$ 62 million) Series A financing was led by Novo Seeds and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...